However, RAAS inhibiting agents might also facilitate the spread of SARS-CoV-2 by increasing expression of ACE2 [5, 6] thus raising the concerns over the continuous use of ACEi and ARB treatment in the context of COVID-19 [7]. The gene discussed is ACE2; the disease is COVID-19.